drugset / Trial / NCT05646719

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719

Phase 3 Completed 333 enrolled Ocuphire Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objectives of this study are: To evaluate the safety and efficacy of Nyxol alone and with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity (DCNVA) in subjects with presbyopia.

Timeline

Start
2022-12-22
Primary completion
2023-10-11
Completion
2023-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentolamine Small molecule 0.75 % Other
Subject Pilocarpine Unknown 0.4 % Other

Indications